Investor Relations

Corporate Profile

Avenue Therapeutics, Inc., a Fortress Biotech (NASDAQ: FBIO) Company, is a specialty pharmaceutical company focused on the development and commercialization of intravenous (IV) tramadol for the management of moderate to moderately severe postoperative pain. IV tramadol may fill a gap in the acute pain market between IV acetaminophen/NSAIDs and IV conventional narcotics. Avenue is currently evaluating IV tramadol in a pivotal Phase 3 program for the management of postoperative pain. Avenue is headquartered in New York City.

Stock Quote

NASDAQ: ATXI 3.66 +0.17 +4.87%
Volume: 45,833 Pricing delayed 20 minutes October 18, 2018 02 04 PM

Press Releases

Latest Presentation

Check back later.

Recent Events

Latest Financials

Annual Report